Back |
home / stock / mbrx / mbrx message board
Subject | By | Source | When |
---|---|---|---|
whytestocks: $MBRX News Article - Moleculin Announces Additional Positive Interim Results in First C | whytestocks | investorshangout | 05/07/2019 2:25:40 PM |
whytestocks: $MBRX News Article - Biotech Brief: Optimistic Outlook Growing for Multi-Billion Dollar | whytestocks | investorshangout | 04/23/2019 12:45:40 PM |
znewcar1: MBRX 168% v82,4M c2.98 f29M H 3.19 not looking strong after hours gap up and slow take off | znewcar1 | investorshangout | 04/22/2019 8:57:21 PM |
whytestocks: $MBRX News Article - MBRX Stock Up 150% on Moleculin Lung Cancer Discovery | whytestocks | investorshangout | 04/22/2019 8:15:40 PM |
whytestocks: $MBRX News Article - Biotech Brief: FDA Fast Tracking Innovative Breakthrough Therapies | whytestocks | investorshangout | 04/18/2019 12:25:39 PM |
News, Short Squeeze, Breakout and More Instantly...
Moleculin Biotech Inc. Company Name:
MBRX Stock Symbol:
NASDAQ Market:
Moleculin Biotech Inc. Website:
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML PR Newswire HOUSTON , July 10, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfoli...
2024-06-17 10:10:00 ET June 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the compan...
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial PR Newswire – 89% of CRc's were subjects with "poor prognosis" cytogenetics and/or mutations – Current median durability of response (mDOR) of CRc's = 6 months and in...